<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443324</url>
  </required_header>
  <id_info>
    <org_study_id>15787</org_study_id>
    <secondary_id>I4T-MC-JVDF</secondary_id>
    <secondary_id>2015-001473-40</secondary_id>
    <secondary_id>KEYNOTE -098</secondary_id>
    <nct_id>NCT02443324</nct_id>
  </id_info>
  <brief_title>A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and preliminary efficacy of the
      combination of the study drug known as ramucirumab plus pembrolizumab in participants with
      locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ)
      adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the
      urothelium, or biliary tract cancer (BTC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline to Measured Progressive Disease (Estimated up to 24 Months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]</measure>
    <time_frame>Baseline to Measured Progressive Disease (Estimated up 24 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]</measure>
    <time_frame>Baseline to Measured Progressive Disease (Estimated up 24 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up 24 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response (TTR)</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up 24 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Progressive Disease or Death of Any Cause (Estimated up 24 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Death from Any Cause (Estimated up 24 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab</measure>
    <time_frame>Predose Day 1 Cycle 1 through Cycle 9 Day 1 (21 Day Cycles)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Carcinoma, Transitional Cell</condition>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort B)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort C)</arm_group_label>
    <arm_group_label>Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort E)</arm_group_label>
    <other_name>LY3009806</other_name>
    <other_name>IMC-1121B</other_name>
    <other_name>Cyramza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort B)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort C)</arm_group_label>
    <arm_group_label>Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)</arm_group_label>
    <arm_group_label>Ramucirumab + Pembrolizumab (Phase 1b Cohort E)</arm_group_label>
    <other_name>MK3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic disease or locally advanced, unresectable disease.

               -  Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented
                  disease progression after 0-2 prior lines of systemic therapy

               -  Has histopathologically confirmed nonsquamous or squamous NSCLC with documented
                  disease progression after 0-3 prior lines of systemic therapy

               -  Has histopathologically confirmed transitional cell carcinoma of the urothelium
                  (bladder, urethra, or renal pelvis) with documented disease progression after 1-3
                  prior lines of systemic therapy

               -  Has histologically confirmed biliary tract adenocarcinoma with documented
                  progression after 1-2 prior lines of systemic therapy

          -  Availability of tumor tissue for biomarker analysis from a newly obtained core or
             excisional biopsy or willing to undergo a tumor biopsy. For first line NSCLC
             participants only, PD-L1 expression should be 1% or higher.

          -  Have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

          -  Has adequate organ function.

          -  Have an anticipated life expectancy of ≥3 months.

        Exclusion Criteria:

          -  Have known brain metastases.

          -  Has received ≥3 lines of prior systemic therapy for gastric or GEJ adenocarcinoma and
             BTC or ≥4 lines for NSCLC or urothelial cancer.

          -  Has active autoimmune disease.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Known active hepatitis B or hepatitis C infection.

          -  Has received any previous systemic therapy targeting vascular endothelial growth
             factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling
             pathways.

          -  Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines
             that do not contain live virus are permitted.

          -  Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior
             to enrollment.

          -  Have an elective or a planned major surgery during the course of the trial or has
             undergone major surgery within 28 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris CEDEX 05</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kochi-Shi</city>
        <zip>780-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yamanashi</city>
        <zip>400-0124</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrialguide.com/en-US/studies/gastroesophageal-junction%20cancer%20(gej)/JVDF#?postal=</url>
    <description>Click here for more information about this study: A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immuno-oncology</keyword>
  <keyword>Vascular Endothelial Growth Factor (VEGF)</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>PD-1</keyword>
  <keyword>carcinoma of the bladder</keyword>
  <keyword>carcinoma of the urethra</keyword>
  <keyword>carcinoma of the ureter</keyword>
  <keyword>carcinoma of the renal pelvis</keyword>
  <keyword>carcinoma of the biliary tract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

